Long non‑coding RNA Fer‑1‑like family member 4 suppresses hepatocellular carcinoma cell proliferation by regulating PTEN in vitro and in vivo

Sun,Xinyi; Zheng,Guoqi; Li,Chunying; Liu,Chendi

doi:10.3892/mmr.2018.9629

Long non‑coding RNA Fer‑1‑like family member 4 suppresses hepatocellular carcinoma cell proliferation by regulating PTEN in vitro and in vivo

Authors:
- Xinyi Sun
- Guoqi Zheng
- Chunying Li
- Chendi Liu
View Affiliations

Affiliations: Department of Gastroenterology, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China
Published online on: November 7, 2018 https://doi.org/10.3892/mmr.2018.9629
Pages: 685-692

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the potential role of long non‑coding RNA Fer‑1‑like family member 4 (FER1L4) in the proliferation of hepatocellular carcinoma (HCC) through the regulation of phosphatase and tensin homolog (PTEN) expression. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression levels of FER1L4 and PTEN mRNA in HCC tissues, and western blotting was performed to measure the protein expression level of PTEN; MTT and colony formation assays were performed to detect the cell proliferative ability. Furthermore, nude mice were injected with transfected HCC cells and the tumor volume and weight were measured. The results indicated that FER1L4 was expressed at a low level in human HCC tissues compared with adjacent normal tissues. Functional studies indicated that FER1L4 may inhibit the proliferative ability of HCC cells. In addition, PTEN was highly expressed in HCC tissues compared with normal adjacent tissues and was positively associated with FER1L4. In addition, it was demonstrated that FER1L4 inhibited the proliferative ability of HCC cells in vitro, and silencing FER1L4 expression by small interfering RNAs promoted the growth of HCC tumors in vivo. Therefore, FER1L4 may be a potent therapeutic target for HCC.

View Figures

View References

1	Li Z, Zhang C, Lou C, Yan F, Mao Y, Hong X and Zhang Y: Comparison of percutaneous cryosurgery and surgical resection for the treatment of small hepatocellular carcinoma. Oncol Lett. 6:239–245. 2013. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. J Gastroenterol Hepatol. 25:657–663. 2010. View Article : Google Scholar : PubMed/NCBI
4	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
5	Conti F, Dall'Agata M, Gramenzi A and Biselli M: Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med. 9:1343–1351. 2015. View Article : Google Scholar : PubMed/NCBI
6	Li CH and Chen Y: Targeting long non-coding RNAs in cancers: Progress and prospects. Int J Biochem Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
7	Guttman M and Rinn JL: Modular regulatory principles of large non-coding RNAs. Nature. 482:339–346. 2012. View Article : Google Scholar : PubMed/NCBI
8	Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al: Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 106:11667–11672. 2009. View Article : Google Scholar : PubMed/NCBI
9	Liu Y, Zhao J, Zhang W, Gan J, Hu C, Huang G and Zhang Y: lncRNA GAS(5) enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci Rep. 5:101592015. View Article : Google Scholar : PubMed/NCBI
10	Liu X, Li D, Zhang W, Guo M and Zhan Q: Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J. 31:4415–4427. 2012. View Article : Google Scholar : PubMed/NCBI
11	Lakhotia SC: Long non-coding RNAs coordinate cellular responses to stress. Wiley Interdiscip Rev RNA. 3:779–796. 2012. View Article : Google Scholar : PubMed/NCBI
12	Paralkar VR and Weiss MJ: A new ‘Linc’ between noncoding RNAs and blood development. Genes Dev. 25:2555–2558. 2011. View Article : Google Scholar : PubMed/NCBI
13	Dhamija S and Diederichs S: From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 139:269–280. 2016. View Article : Google Scholar : PubMed/NCBI
14	Song H, Sun W, Ye G, Ding X, Liu Z, Zhang S, Xia T, Xiao B, Xi Y and Guo J: Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J Transl Med. 11:2252013. View Article : Google Scholar : PubMed/NCBI
15	Liu Z, Shao YF, Tan L, Shi HJ, Chen SC and Guo JM: Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumor Biol. 35:9613–9617. 2014. View Article : Google Scholar
16	Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F and Yan D: Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. Cancer Sci. 106:1323–1332. 2015. View Article : Google Scholar : PubMed/NCBI
17	Xia T, Chen SC, Jiang Z, Shao Y, Jiang X, Li P, Xiao B and Guo J: Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci Rep. 5:134452015. View Article : Google Scholar : PubMed/NCBI
18	Qiao Q and Li H: LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem Biophys Res Commun. 478:507–512. 2016. View Article : Google Scholar : PubMed/NCBI
19	Malaney P and Dave V: Loss of PTEN cooperates with mutant KRAS initiating EMT and increased stemness in a mouse model of lung cancer. Mol Cancer Res. 12:B092014. View Article : Google Scholar
20	Takashi K, Naozumi H, Kazuyoshi I, Koji S, Daisuke A, Tomomi O and Yoshinori H: Gene modulation of phosphorylation sites in tumor suppressor PTEN inhibits hypoxia-induced phenotype changes through epithelial-mesenchymal transition (EMT) in lung cancer. Am J Respirat Crit Care Med. 183:A35032011.
21	Cho BC, Kim SM, Hong YK and Kim H: Increased PTEN instability-mediated Akt activation confers acquired resistance to cetuximab and increased migration/invasion potentials in non-small cell lung cancer. Clin Exp Metastas. 28:230. 2011.
22	Sun Y, Tian H and Wang L: Effects of PTEN on the proliferation and apoptosis of colorectal cancer cells via the phosphoinositol-3-kinase/Akt pathway. Oncol Rep. 33:1828–1836. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhang D, Zhou PH, Wang W, Wang X, Li J, Sun X and Zhang L: MicroRNA-616 promotes the migration, invasion and epithelial-mesenchymal transition of HCC by targeting PTEN. Oncol Rep. 35:366–374. 2016. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Lindl T, Gross U, Ruhdel I, von Aulock S and Völkel M: Guidance on determining indispensability and balancing potential benefits of animal experiments with costs to the animals with specific consideration of EU directive 2010/63/EU. ALTEX. 29:219–228. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ray MA, Johnston NA, Verhulst S, Trammell RA and Toth LA: Identification of markers for imminent death in mice used in longevity and aging research. J Am Assoc Lab Anim Sci. 49:282–288. 2010.PubMed/NCBI
27	Broeckx BJG, Hitte C, Coopman F, Verhoeven GE, De Keulenaer S, De Meester E, Derrien T, Alfoldi J, Lindblad-Toh K, Bosmans T, et al: Improved canine exome designs, featuring ncRNAs and increased coverage of protein coding genes. Sci Rep. 5:128102015. View Article : Google Scholar : PubMed/NCBI
28	Qu ZP and Adelson DL: Identification and comparative analysis of ncRNAs in human, mouse and zebrafish indicate a conserved role in regulation of genes expressed in brain. PLoS One. 7:e522752012. View Article : Google Scholar : PubMed/NCBI
29	Ferro M, Altieri V, Montanaro V and Cimmino A: Ultraconserved region (Ucrs) encoding ncrnas involvement in bladder cancer tumorigenesis: A new(P)layer in the ‘dark matter’. Anticancer Res. 33:22662013.
30	Hayes EL and Lewis-Wambi JS: Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA. Breast Cancer Res. 17:402015. View Article : Google Scholar : PubMed/NCBI
31	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
32	Louro R, Smirnova AS and Verjovski-Almeida S: Long intronic noncoding RNA transcription: Expression noise or expression choice? Genomics. 93:291–298. 2009. View Article : Google Scholar : PubMed/NCBI
33	Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell. 145:178–181. 2011. View Article : Google Scholar : PubMed/NCBI
34	Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361. 2011. View Article : Google Scholar : PubMed/NCBI
35	Liang M, Huang J, He J, Yi Q, Zhang Z, Tu L, Ma D and Yan J: FER1L4: A potential plasma biomarker to identify gastric cancer with lymph node invasion. Int J Clin Exp Pathol. 9:1982–1988. 2016.
36	Lotan TL, Carvalho FLF, Peskoe SB, Hicks JL, Good J, Fedor H, Humphreys E, Han M, Platz EA, Squire JA, et al: PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 28:128–137. 2015. View Article : Google Scholar : PubMed/NCBI
37	Dawson H, Koelzer V, Karamitopoulou E, Lugli A and Zlobec I: The role of the tumor suppressor PTEN in colorectal cancer is highly dependent on the tumor area. Lab Invest. 95:156a2015.
38	Keniry M and Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 27:5477–5485. 2008. View Article : Google Scholar : PubMed/NCBI
39	Yazdani Y, Farazmandfar T, Azadeh H and Zekavatian Z: The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci. 23:92016. View Article : Google Scholar : PubMed/NCBI
40	Xie SM, Lu ZY, Lin YZ, Shen LJ and Yin C: Upregulation of PTEN suppresses invasion in Tca8113 tongue cancer cells through repression of epithelial-mesenchymal transition (EMT). Tumor Biol. 37:6681–6689. 2016. View Article : Google Scholar
41	Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, Rha SY and Kim HS: PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. Oncolo. 88:76–85. 2015. View Article : Google Scholar
42	Guo C, Song WQ, Sun P, Jin L and Dai HY: LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci. 22:1002015. View Article : Google Scholar : PubMed/NCBI